Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme

Journal of Neurosurgery

Volumn 100, Issue 2, 2004, Pages 320-327

  Hjortland, Geir Olav ^a   Garman Vik, Solveig Suzanne ^b   Juell, Siri ^b   Olsen, Øyvind Edon ^b   Hirschberg, Henry ^b   Fodstad, Øystein ^b   Engebraaten, Olav ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NONE

Author keywords

Animal model; Glioma; Immunotoxin; Rat

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOTOXIN; MONOCLONAL ANTIBODY; PROTEIN S 100; PSEUDOMONAS EXOTOXIN A; PSEUDOMONAS EXOTOXIN A MONOCLONAL ANTIBODY 9.2.27 CONJUGATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN BIOPSY; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DISEASE MARKER; DRUG CONJUGATION; DRUG EFFECT; DRUG EFFICACY; DRUG SYNTHESIS; DRUG TARGETING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT STRAIN; SURVIVAL TIME; XENOGRAFT;

EID: 0942287653     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.2004.100.2.0320     Document Type: Article

References (31)

1. Bjerkvig R, Tonnesen A, Laerum OD, et al: Multicellular tumor spheroids from human gliomas maintained in organ culture. J Neurosurg 72:463-475, 1990
2. Bumol TF, Wang QC, Reisfeld RA, et al: Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth. Proc Natl Acad Sci USA 80:529-533, 1983
3. Burg MA, Pasqualini R, Arap W, et al: NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res 59:2869-2874, 1999
4. Carter P: Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1:118-129, 2001
5. Chekenya M, Enger PO, Thorsen F, et al: The glial precursor proteoglycan, NG2, is expressed on tumour neovasculature by vascular pericytes in human malignant brain tumours. Neuropathol Appl Neurobiol 28:367-380, 2002
6. Chekenya M, Hjelstuen M, Enger PO, et al: NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin. FASEB J 16:586-588, 2002
7. De Leij L, Helrich W, Stein R, et al: SCLC-cluster-2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP-2. Int J Cancer Suppl 8:60-63, 1994
8. Engebraaten O, Hjortland GO, Hirschberg H, et al: Growth of pre-cultured human glioma specimens in nude rat brain. J Neurosurg 90:125-132, 1999
9. Engebraaten O, Hjortland GO, Juell S, et al: Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals. Int J Cancer 97:846-852, 2002
10. Frankel AE, Kreitman RJ, Sausville EA: Targeted toxins. Clin Cancer Res 6:326-334, 2000
11. Godal A, Fodstad O, Pihl A: Studies on the mechanism of action of abrin-9.2.27 immunotoxin in human melanoma cell lines. Cancer Res 47:6243-6247, 1987
12. Godal A, Kumle B, Pihl A, et al: Immunotoxins directed against the high-molecular-weight melanoma-associated antigen. Identification of potent antibody-toxin combinations. Int J Cancer 52:631-635, 1992
13. Gupta T, Sarin R: Poor-prognosis high-grade gliomas: evolving an evidence-based standard of care. Lancet Oncol 3:557-564, 2002
14. Hall WA: Immunotoxin treatment of brain tumors. Methods Mol Biol 166:139-154, 2001
15. Hall WA: Targeted toxin therapy for malignant astrocytoma. Neurosurgery 46:544-552, 2000
16. Hall WA, Fodstad O: Immunotoxins and central nervous system neoplasia. J Neurosurg 76:1-12, 1992
17. Hall WA, Godal A, Juell S, et al: In vitro efficacy of transferrin-toxin conjugates against glioblastoma multiforme. J Neurosurg 76:838-844, 1992
18. Husain SR, Behari N, Kreitman RJ, et al: Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy. Cancer Res 58:3649-3653, 1998
19. Kleihues P, Cavenee WK: Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press, 2000
20. Kounnas MZ, Morris RE, Thompson MR, et al: The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J Biol Chem 267:12420-12423, 1992
21. Laske DW, Youle RJ, Oldfield EH: Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3:1362-1368, 1997
22. Morgan AC Jr, Galloway DR, Reisfeld RA: Production and characterization of monoclonal antibody to a melanoma specific glycoprotein. Hybridoma 1:27-36, 1981
23. Myklebust AT, Godal A, Pharo A, et al: Eradication of small cell lung cancer cells from human bone marrow with immunotoxins. Cancer Res 53:3784-3788, 1993
24. Pluschke G, Vanek M, Evans A, et al: Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc Natl Acad Sci USA 93:9710-9715, 1996
25. Pouly S, Prat A, Blain M, et al: NG2 immunoreactivity on human brain endothelial cells. Acta Neuropathol 102:313-320, 2001
26. Russell DS, Rubinstein LJ: Pathology of Tumors of the Nervous System, ed 5. Baltimore: Williams & Wilkins, 1989
27. Schrappe M, Bumol TF, Apelgren LD, et al: Long-term growth suppression of human glioma xenografts by chemoimmunoconjugates of 4-desacetylvinblastine-3-carboxyhydrazide and monoclonal antibody 9.2.27. Cancer Res 52:3838-3844, 1992
28. Schrappe M, Klier FG, Spiro RC, et al: Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. Cancer Res 51:4986-4993, 1991
29. Shoshan Y, Nishiyama A, Chang A, et al: Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. Proc Natl Acad Sci USA 96:10361-10366, 1999
30. Tordsson JM, Ohlsson LG, Abrahmsen LB, et al: Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma. Cancer Immunol Immunother 48:691-702, 2000
31. Zdanovsky AG, Zdanovskaia MV, Strickland D, et al: Ligand-toxin hybrids directed to the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein exhibit lower toxicity than the native Pseudomonas exotoxin. J Biol Chem 271:6122-6128, 1996